Abstract. A pre-metastatic niche (PMN) facilitates cancer metastasis through mobilization and recruitment of bone marrow-derived cells (BMDCs) and associated factors. In bone marrow, hematogenous cells, including osteoclasts, macrophages and lymphocytes, and mesenchymal cells, including mesenchymal stem cells, osteoblasts and adipocytes, are involved in PMN formation. Patients with lung cancer and metastasis have a poor prognosis and shortened median survival time. Bone marrow has been considered fertile ground for dormant and proliferating tumor cells, and mobilizing and recruiting BMDCs and immune cells can establish a PMN. However, the role of BMDCs in PMN formation is not yet fully understood. The present study aimed to investigate the association between BMDCs and PMN in bone marrow tissue samples. The results demonstrated that bone marrow served an important role in lung cancer progression and that eight pathways were potentially involved, including ‘T-cell receptor signaling pathway’, ‘osteoclast differentiation’, ‘MAPK signaling pathway’, ‘VEGF signaling pathway’, ‘leukocyte transendothelial migration’, ‘signaling pathways regulating the pluripotency of stem cells’, ‘oxytocin signaling pathway’ and ‘cell adhesion molecules (CAMs)’. In addition, the present study investigated the role of BMDCs in facilitating lung cancer metastasis. In conclusion, the results from the present study suggested that molecular alterations in gene expression may provide a novel signature in lung cancer, which may aid in the development of novel diagnostic and therapeutic strategies for patients with lung cancer and bone metastasis.

Introduction

Cellular components of bone marrow have important roles in pre-metastatic niche (PMN) formation (1). In lung cancer, distant metastases are common and this type of cancer usually spreads to the bone (39%), liver (35%) and central nervous system (47%) (2). Patients with lung cancer and metastasis have a poor prognosis with a shortened median survival time following diagnosis (3). In order to metastasize, tumor cells need an organ with a suitable environment for their growth and proliferation, which is defined as the metastatic niche (4). Cancer cells initiate and establish the environmental surroundings required for future metastasis through various mechanisms, including cancer cell intravasation, immune evasion and arrival at designated site, extravasation, colonization and tumor growth (5). The bone marrow microenvironment has been described as fertile ground for dormant and proliferating tumor cells. For example, bone marrow and tumor cells can modify the activity of osteoclasts (6), and pro-tumorigenic cells, including mesenchymal stem cells, have been reported to serve a crucial role in promoting osteolytic bone metastasis and tumor cell proliferation in the tumor microenvironment (7). Additional tumor-derived factors have been reported to promote tumor progression. These factors can stimulate the differentiation of immature myeloid cells into strong immune response suppressors and therefore inhibit the activation of antitumor T cells (8).

Numerous factors, including tumor-derived secreted factors and extracellular vesicles, are involved in PMN establishment (5). In addition, other cell types, including bone

Key words: bone marrow-derived cells, next generation sequencing, bioinformatics, lung cancer
marrow-derived cells (BMDCs) such as mesenchymal stem cells and regulatory T cells, are directed to the secondary organs. Once these cells have reached the PMN, they modify its local microenvironment through inflammatory cytokines, growth factors and proangiogenic molecules to facilitate tumor cell colonization and proliferation, and therefore promote tumor metastasis (4,5,9).

Notably, a PMN is established through the combination of various tumor-derived factors, tumor-mobilized BMDCs and the local environment (5,9). However, the role of BMDCs in PMN formation is not yet fully understood. In the present study, it was hypothesized that lung cancer cells can remotely modify BMDCs, which could therefore become actively involved in PMN establishment in target organs. The present study aimed to investigate the role of BMDCs in lung cancer metastasis from a macroscopic perspective (Fig. 1). To do so, bone marrow tissue samples were examined by next generation sequencing (NGS).

Materials and methods

Cell culture. The LL/2 mouse Lewis lung carcinoma (LLC) cell line [LLC1; American Type Culture Collection (ATCC)® CRL-1642™] was purchased from the ATCC (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in an incubator containing 5% CO₂ at 37°C.

BMDCs isolation. Male C57BL/6J mice (age, 8 weeks; weight, 20-25 g) were obtained from the National Laboratory Animal Center (Taipei, Taiwan). These mice were housed at a constant temperature (21±1°C) and humidity (55-65%) under a 12-h light/dark cycle. Mice had free access to food and water. Animal experiments were performed according to the Institutional Animal Care and Use Committee, with the approval of the Animal Care and Use Committee of the School of Kaohsiung Medical University (Kaohsiung, Taiwan). The study group contained six mice that were injected with 1×10⁶ LLC cells, whereas the control group comprised six mice that received sham injection with DMEM. All injections were administered into the tail vein. Mice were sacrificed after 10 days. The LLC-BMDCs and normal-BMDCs were obtained after femoral bone removal, followed by flushing the bone marrow out from the femurs bilaterally with PBS. The collected BMDCs were suspended in DMEM (10). The BMDCs from mice contained in each group were pooled prior to further experiments.

RNA sequencing. Total RNA was isolated from BMDCs using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. RNA purity was measured by assessing optical density (OD₂₆₀nm/OD₂₈₀nm) absorbance ratio (1.96 for normal-BMDCs and 2.03 for LLC-BMDCs) with an ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc., Wilmington, DE, USA). RNA concentration was determined according to the RNA integrity number (RIN; RIN, 10 for normal-BMDCs and LLC-BMDCs) with an Agilent Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA).

Library preparation and deep sequencing were performed using Illumina Solexa system (Illumina, Inc., San Diego, CA, USA) according to the manufacturer's protocol, as previously described (11,12). For small RNA sequencing, total RNA was reverse transcribed using TruSeq Small RNA Sample Prep kit (Illumina, Inc.) following the manufacturer's instructions, and cDNA (18-40-nucleotide RNA fragments; 140-155 nucleotides in length with both adapters) was sequenced on the Illumina system (75 single-end cycles). After trimming or removing low-quality data using Trimmomatic software version 0.36 (13), the qualified reads were analyzed using miRDeep2 software (miRBase 21) (14) and the human genome from the University of California Santa Cruz database (https://genome.ucsc.edu/). Micro (mi)RNAs with low levels [<1 normalized read per million (RPM)] in normal- and LLC-BMDCs were excluded. For transcriptome sequencing, the library constructed with SureSelect Strand Specific RNA Library Preparation kit (Agilent Technologies, Inc.) was sequenced using a TruSeq SBS kit on the Solexa platform (Illumina NextSeq: 75 cycles, single-end or paired-end). After trimming or removing low-quality data using Trimomatic software (13), the qualified reads were analyzed using TopHat/Cufflinks (15) and Ensembl (https://www.ensembl.org/index.html) databases. Genes with low expression levels (<0.3 fragment per kilobase of transcript per million mapped reads) in normal- and LLC-BMDCs were excluded. The criteria of differentially expressed genes (DEGs) were -log₁₀(P-value)>1.3 and >2 fold change (FC), and -log₁₀(q-value)>0.6 and q<0.25 for stringent criteria.

miRNA database analysis. Putative genes targeted by candidate miRNAs were predicted using the miRmap database (http://cegg.unige.ch/mirmap) (16). The search criteria of the putative targeted genes by miRNAs were ‘mice species’ and a miRmap score of >99.0. Potential miRNA interactions were also searched using the miRMap TargetScan (http://www.targetscan.org/vert_71/) and miRDB (http://www.mirdb.org/) databases.

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database analysis. The functions of DEGs were studied by analyzing the genes of interest according to previous studies (11,12). The Database for Annotation, Visualization and Integrated Discovery (https://david.ncifcrf.gov) was used to conduct GO and KEGG database analyses. Briefly, a panel of potential genes was classified into clusters of associated biological functions, signaling pathways and diseases by calculating the similarity of global annotation profiles using the agglomeration algorithm method.

Results

Gene expression profiling and miRNA alterations in LLC-BMDCs versus normal BMDCs. The differentially down-regulated (green spots, left panel) and upregulated (red spots, right panel) genes in the LLC-BMDCs versus normal-BMDCs were presented as a volcano plot (Fig. 2). A total of 820 genes with -log₁₀(P-value)>1.3 and >2 FC were chosen for further analyses (Fig. 2A). However, when using the following more stringent criteria: -log₁₀(q-value)>0.6 and FDR<0.25, only 139 genes were detected (Fig. 2B). Using the stringent criteria, too few genes were obtained to be analyzed.
The 820 genes expressed on the RNA sequencing heatmap (Fig. 3; left panel) revealed DEGs with FC>2 (either increase or decrease). The ‘gene’ Venn diagram demonstrated that 309 genes were upregulated and 511 were downregulated in the LLC-BMDCs compared with normal-BMDCs (Fig. 3). NGS miRNA heatmap (Fig. 3; right panel) analysis highlighted 161 differentially expressed miRNAs with FC>2 and P<0.05. Results from the ‘miRNA’ Venn diagram revealed the miRNAs with a threshold of RPM>1, which included 55 precursor miRNAs that were downregulated and 106 precursor miRNAs that were upregulated in BDMCs. The ‘targets’ Venn diagram exhibited the predicted genes of the miRNAs from the ‘miRNA’ Venn diagram using the miRmap online database. The selection threshold was a miRmap score ≥99.0. The intersection in the Venn diagram between ‘genes’ and ‘targets’ revealed 37 potential miRNA-mRNA interactions (Fig. 3), of which 34 included downregulated and three included upregulated genes (Table I).
KEGG analysis of DEGs in LLC-BMDCs. The three upregulated and 34 downregulated genes in the ‘genes’ and ‘targets’ diagram (Fig. 3) were mapped to KEGG pathways. The results identified eight potential pathways that may involve the LLC-BMDCs, including the ‘T-cell receptor signaling pathway’, ‘osteoclast differentiation’, ‘MAPK signaling pathway’, ‘VEGF signaling pathway’, ‘leukocyte transendothelial migration’, ‘signaling pathways regulating pluripotency of stem cells’, ‘oxytocin signaling pathway’ and ‘cell adhesion molecules (CAMs)’ (Table II).

Analysis of DEGs in LLC-BMDCs versus normal-BMDCs. DEGs were analyzed using GO in order to investigate the enriched functions of the 820 potential miRNA-mRNA interactions. The top 20 cellular components, top 20 biological processes and top 20 molecular functions of the DEGs in the LLC-BMDCs are presented in Fig. 4A-C. All top 20 results, including molecular functions, biological processes and cellular components, were statistically significant (P<0.05).

KEGG pathway enrichment analysis of 820 differentially expressed mRNAs in LLC-BMDCs versus normal-BMDCs. The top 20 pathways with the most significant enrichment are presented in Fig. 5, where each marker represents a KEGG pathway. The fold enrichment represents the ratio of the proportion of DEGs annotated to the pathway to all genes. The larger the fold enrichment score, the more significant the enrichment level of the DEGs in the pathway. In addition, the greater $-\log_{10}(P$-value), the more reliable the enrichment significance of the DEGs in the pathway. Two pathways (‘Hematopoietic cell lineage’ and ‘Primary immunodeficiency’) were most significantly enriched in LLC-BMDCs (Fig. 5).

Potential miRNA-mRNA interactions from miRmap, TargetScan and miRDB databases. The miRmap (selection criteria: miRmap score >97.0), TargetScan (selection criteria: TargetScan score >99.0) and miRDB (selection criteria: miRDB score >95.0) databases were used to explore the potential miRNA-mRNA interactions of the miRNAs with >2 FC (Fig. 6). By combining the results from the three databases, 23 miRNA-mRNA interactions were identified (Table III). Due to the insufficiency of gene interactions, the miRmap and miRDB scores were modified to >99 and >95.0, respectively.

Discussion

Patients with lung cancer and metastasis have a poor prognosis. Notably, PMN establishment is crucial for the development of distant metastases. The predicted mRNAs of specific miRNAs imply potential regulatory mechanisms of miRNA targets in the formation of a PMN. In the present study, ‘gene’ and miRNA-predicted ‘target’ genes were matched to strengthen the significance of the selected genes that mediate PMN. Eight potential pathways that may be involved in the bone marrow modification observed during lung cancer progression were revealed. These eight pathways were derived from the common genes of the ‘genes’ and ‘targets’, as follows: ‘T-cell receptor signaling pathway’, ‘MAPK signaling pathway’, ‘osteoclast differentiation’, ‘VEGF signaling pathway’, ‘leukocyte transendothelial migration’, ‘signaling pathways regulating pluripotency of stem cells’, ‘oxytocin signaling pathway’ and ‘cell adhesion molecules (CAMs)’.

In addition, the present study analyzed the KEGG pathways derived from mRNAs with >2 FC in the LLC-BMDCs compared with the control-BMDCs. Results demonstrated that three
Table I. Potential miRNA-mRNA interactions in LLC-BMDCs.

| Gene symbol | Associated miRNA | Gene Description | log₂ ratio (LLC/Ctrl) | Expression |
|-------------|------------------|------------------|-----------------------|------------|
| BMPR1A      | mmu-miR-135a-5p  | Bone morphogenetic protein receptor, type 1A | 2.80 | Up |
| LRRCT5B     | mmu-miR-150-5p   | Leucine rich repeat containing 75B | 5.41 | Up |
| FAM217B     | mmu-miR-195a-5p  | Family with sequence similarity 217, member B | 2.93 | Up |
| AXL         | mmu-miR-1249-5p  | AXL receptor tyrosine kinase | -2.89 | Down |
| PHYHIP      | mmu-miR-1249-5p  | Phytanoyl-CoA hydroxylase interacting protein | -1.73 | Down |
| FOSB        | mmu-miR-1249-5p  | FosB proto-oncogene, AP-1 transcription factor subunit | -1.75 | Down |
| CACNA1E     | mmu-miR-1249-5p  | Calcium channel, voltage-dependent, R type, α1E subunit | -1.92 | Down |
| MPP2        | mmu-miR-1249-5p  | Membrane protein, palmitoylated 2 (MAGUK p55 subfamily member 2) | -1.79 | Down |
| ZBTB4       | mmu-miR-1249-5p  | Zinc finger and BTB domain containing 4 | -2.02 | Down |
| ADAM11      | mmu-miR-1249-5p  | A disintegrin and metallopeptidase domain 11 | -1.69 | Down |
| OTUB2       | mmu-miR-3085-3p  | OTU domain, ubiquitin aldehyde binding 2 | -1.87 | Down |
| NR1D2       | mmu-miR-148a-5p  | Nuclear receptor subfamily 1, group D, member 2 | -1.93 | Down |
| LYNX1       | mmu-miR-1249-5p  | Ly6/neurotoxin 1 | -2.04 | Down |
| Fhl1        | mmu-miR-1249-5p  | Four and a half LIM domains 1 | -2.91 | Down |
| Cd4         | mmu-miR-1249-5p  | CD4 antigen | -2.09 | Down |
| EHD3        | mmu-miR-1249-5p  | EH-domain containing 3 | -1.68 | Down |
| DNASE1L3    | mmu-miR-1249-5p  | Deoxyribonuclease 1-like 3 | -3.31 | Down |
| SDC3        | mmu-miR-1249-5p  | Syndecan 3 | -2.92 | Down |
| NFATC2      | mmu-miR-1249-5p  | Nuclear factor of activated T cells 2 | -1.33 | Down |
| TNIK        | mmu-miR-1198-3p  | TRAF2 and NCK interacting kinase | -1.71 | Down |
| PDE4B       | mmu-miR-1249-5p  | Phosphodiesterase 4B | -1.55 | Down |
| BCL7A       | mmu-miR-1249-5p  | BAF chromatin remodeling complex subunit BCL7A | -1.50 | Dpwn |
| DUSP16      | mmu-miR-1249-5p  | Dual specificity phosphatase 16 | -1.64 | Down |
| SORBS2      | mmu-miR-21a-3p   | Sorbin and SH3 domain containing 2 | -4.21 | Down |
| THY1        | mmu-miR-1249-5p  | Thy-1 cell surface antigen | -1.48 | Down |
| CAPN5       | mmu-miR-1249-5p  | Calpain 5 | -1.53 | Down |
| TRIM58      | mmu-miR-1249-5p  | Tripartite motif-containing 58 | -1.95 | Down |
| CAMK1D      | mmu-miR-1249-5p  | Calcium/calmodulin-dependent protein kinase ID | -1.15 | Down |
| FHDC1       | mmu-miR-193b-3p  | FH2 domain containing 1 | -2.42 | Down |
| SBK1        | mmu-miR-1249-5p  | SH3-binding kinase 1 | -2.25 | Down |
| DUSP18      | mmu-miR-1249-5p  | Dual specificity phosphatase 18 | -1.65 | Down |
| 2900026A02RIK | mmu-miR-1249-5p | RIKEN cDNA 2900026A02 gene | -1.90 | Down |
| MAPK11      | mmu-miR-1249-5p  | Mitogen-activated protein kinase 11 | -2.78 | Down |
| SH3PXD2A    | mmu-miR-1249-5p  | SH3 and PX domains 2A | -2.08 | Down |
| CECR2       | mmu-miR-1249-5p  | Cat eye syndrome chromosome region, candidate 2 | -2.43 | Down |
| SOX4        | mmu-miR-129-5p   | SRY-box 4 | -1.36 | Down |
| ACSF2       | mmu-miR-1249-5p  | Acyl-CoA synthetase family member 2 | -1.39 | Down |

miRNA, microRNA.
pathways were identical, including the ‘T-cell receptor signaling pathway’, ‘MAPK signaling pathway’ and ‘cellular adhesion molecules (CAMs)’.

The T-cell receptor (TCR) signaling pathway represents a branching network, which is initiated by cognate peptide-major histocompatibility complex molecules, and is associated with the mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) signaling pathways (17). It has also been reported that the TCR signaling pathway involves the mobilization of transcription factors. Subsequently, it serves a crucial role in T-cell gene expression and is essential for T-cell growth and differentiation (17). Furthermore, it induces expression of the inducible costimulatory molecule (ICOS) and programmed cell death 1 (PD1), which are members of the CD28 family. ICOS and PD1 can control the sustained phase of T-cell signaling (18), whereas PD1 inhibitors can target the binding between T cell PD1 receptors and PD-ligands 1 and 2. PD1 inhibitors have also been reported to block inhibitory signaling, which results in the activation of T-cell effector function, which provides an anticancer potential for activated T cells (19).

The Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (ERK) signaling pathway, which is one of the major intracellular axes that regulate intracellular signaling trafficking, is associated with cell proliferation, growth, invasion, metastasis, resistance to apoptosis and angiogenesis in lung cancer (20). It has been reported that the MAPK pathway interferes in non-small cell lung cancer tumorogenesis through terminal differentiation-induced noncoding RNA (21), although the role of the MAPK/ERK pathway in lung cancer treatment remains unclear. The therapeutic inhibition of elements from this pathway has been reported to be beneficial in cancer treatment, including colorectal and ovarian cancer (22). However, treatment with small inhibitors that specifically target proteins from the MAPK/ERK pathway can lead to the development of secondary malignancies. For example, Raf inhibitors have been reported to potentially induce abnormal skin cell proliferation and cause secondary squamous cell cancers (22).

CAMs, which comprise cadherins, integrins, selectins and members of the immunoglobulin family, are important components involved in cell-to-cell and cell-to-extracellular matrix anchoring. Their main roles are to maintain cell and tissue structure, cell signaling, tissue repair and wound healing (23). In addition, integrins serve an important role in platelet aggregation, hematopoietic cell mobilization, neoangiogenesis and stromal function. They are also associated with bone metastasis, which suggests that they may represent potential novel therapeutic targets in the prevention and treatment of bone metastasis (24).

### Table II. KEGG analysis of differentially expressed genes predicted by miRmap in LLC-BMDCs.

| KEGG pathway                                  | Count | P-value | Upregulated genes         | Downregulated genes        | Fold enrichment |
|----------------------------------------------|-------|---------|---------------------------|---------------------------|-----------------|
| T-cell receptor signaling pathway            | 3     | 0.01    | *Cd4*, *Mapk11*, *Nfatc2* | *Fosb*, *Mapk11*, *Nfatc2* | 18.56           |
| Osteoclast differentiation                    | 3     | 0.01    | *Dusp16*, *Mapk11*, *Cacna1e* | *Mapk11*, *Nfatc2*        | 15.32           |
| MAPK signaling pathway                        | 3     | 0.05    | *Dusp16*, *Mapk11*, *Cacna1e* | *Mapk11*, *Nfatc2*        | 7.63            |
| VEGF signaling pathway                        | 2     | 0.08    | *Mapk11*, *Nfatc2*        | *Mapk11*, *Thy1*          | 21.44           |
| Leukocyte transendothelial migration           | 2     | 0.16    | *Mapk11*, *Nfatc2*        | *Mapk11*, *Thy1*          | 10.63           |
| Signaling pathways regulating pluripotency of stem cells | 2 | 0.18    | *BMPRIA*                   | *Mapk11*                  | 9.32            |
| Oxytocin signaling pathway                    | 2     | 0.20    | *Camk1d*, *Nfatc2*        | *Ccam2*, *Sdc3*           | 8.14            |
| Cell adhesion molecules (CAMs)                | 2     | 0.21    | *Ccam2*, *Sdc3*           | *Ccam2*, *Sdc3*           | 7.94            |

### Table III. Potential miRNA-mRNA interactions of miRNAs with 2-fold change validated in miRmap, TargetScan and miRDB databases.

| miRNAs          | Gene symbol |
|-----------------|-------------|
| mmu-miR-33-5p   | Abca1       |
| mmu-miR-205-5p  | Lrrk2       |
| mmu-miR-129-5p  | Cdc42ep3    |
| mmu-miR-151-3p  | Ago2        |
| mmu-miR-205-5p  | Cdh11       |
| mmu-miR-342-3p  | Fam208a     |
| mmu-miR-150-5p  | Prkar1a     |
| mmu-miR-342-3p  | Fam53c      |
| mmu-miR-136-5p  | Mtmr4       |
| mmu-miR-411-5p  | Pxd1        |
| mmu-miR-342-3p  | Rictor      |
| mmu-miR-150-5p  | Prickle2    |
| mmu-miR-129-5p  | Glicci      |
| mmu-miR-129-5p  | Chmp2b      |
| mmu-miR-455-5p  | Yipf6       |
| mmu-miR-150-5p  | Myb         |
| mmu-miR-129-5p  | ZFP36L1     |
| mmu-miR-129-5p  | BACH2       |
| mmu-miR-455-5p  | ADD3        |
| mmu-miR-147-3p  | NDUFA4      |
| mmu-miR-33-5p   | CNTN4       |
| mmu-miR-409-3p  | ZDHHC20     |
| mmu-miR-33-5p   | SLC12A5     |

miRNA, microRNA.
For example, CAMs, including CD44, N-cadherin, neural cell adhesion molecule and integrins, are involved in the metastatic cascade observed in a metastatic neuroblastoma model (25).

Osteoclast differentiation is associated with bone metastasis in lung cancer. Non-small cell lung cancer can metastasize to the bone, which results in bone osteolytic lesions via osteoclast...
lineage activation. Through the downregulation of the receptor activator of NF-κB signaling pathway, osteoclast differentiation attenuates osteoclastogenesis and reduces osteolysis following bone metastasis (26).

Additional pathways predicted in this study, such as VEGF, leukocyte transendothelial migration, cancer stem cells, etc., are associated with lung cancer metastasis. To support cellular function, tumor cells release VEGF that stimulates angiogenesis.
through vascular sprouting, intussusception and incorporation of bone marrow-derived endothelial precursors (27). In gastric cancer, celecoxib has been used as an inhibitor of cysteine and glycine rich protein 1, thrombospondin 1, myosin light chain 9, filamin A, actinin α1, vinculin, laminin subunit γ2 and claudin 1 expression, and can also suppress leukocyte transendothelial migration and focal adhesion, which highlights its anti-gastric cancer effect (28). Furthermore, cancer stem cells possess self-renewal ability and are involved in the initiation of cancer, malignant transformation and metastatic progression, and in the post-treatment recurrence of various types of human cancer (29). Understanding the underlying mechanisms of transcription factors associated with pluripotency is therefore crucial to clarify human carcinogenesis.

In addition, the hypothalamic nonapeptide, oxytocin, serves as a tumor growth regulator by activating specific G-coupled transmembrane receptor through oxytocin receptor. Oxytocin attenuates proliferation of cancer cells that originate from epithelium, nerves and bone (30).

In conclusion, results from the present study demonstrated that bone marrow may serve a crucial role in mediating lung cancer metastasis. Data revealed that numerous pathways were involved in the LLC-BMDC microenvironment, including the ‘T-cell receptor signaling pathway’, ‘MAPK signaling pathway’, ‘osteoclast differentiation’, ‘VEGF signaling pathway’, ‘leukocyte transendothelial migration’, ‘signaling pathways regulating pluripotency of stem cells’, ‘oxytocin signaling pathway’ and ‘cell adhesion molecules (CAMs)’. These eight pathways were all associated with cancer progression. In addition, the present study provided macroscopic evidence of the association between lung cancer cells and BMDCs (Fig. 7).

Present findings suggested that these genetic interactions may be associated with lung cancer cell progression. Molecular alterations in gene expression may therefore represent a novel signature in lung cancer, which may be used to develop diagnostic and therapeutic strategies for patients with lung cancer and bone metastasis. Further investigation is required to study the role of BMDCs in the bone microenvironment in lung cancer metastasis, and to identify the main cells that mediate bone metastasis in lung cancer.

Acknowledgements
The authors would like to thank Mr. Chi-Hsien Chou and other staff members of the Center for Research Resources and Development of Kaohsiung Medical University for their assistance in bioinformatics analysis.

Funding
This study was supported by the Ministry of Science and Technology (grants nos. MOST 107-2314-B-037-107-MY3, MOST 106-2314-B-037-016-MY2 and MOST 106-2314-B-037-064), the Kaohsiung Medical University Hospital (grants nos. KMUHS10701, KMUHS10712 and KMUH103-3R09) and the Kaohsiung Medical University (grants nos. 105KMUOR05, KMU-DK108003 and KMU-DK108008).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
WAC and JYH designed the study. WAC, YMT, YCT, CYW, KFC, CTL, JYH, YLH, and PLK analyzed the data and interpreted the results. WAC, YMT and JYH wrote the manuscript. The final version of the manuscript has been read and approved by all authors.

Ethical approval and consent to participate
Animal experiments were performed according to the Institutional Animal Care and Use Committee, and with the
approval of the Animal Care and Use Committee of the School of Kaohsiung Medical University.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827, 2005.
2. Rijhimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J and Hemminki K: Metastatic sites and survival in lung cancer. Lung Cancer 86: 78-84, 2014.
3. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12: 6243s-6249s, 2006.
4. Peinado H, Zhang H, Matei IR, Costa-Silva B, Hoshino A, Rodrigues G, Psaila B, Kaplan RN, Bromberg JF, Kang Y, et al: Pre-metastatic niches: Organ-specific homes for metastases. Nat Rev Cancer 17: 302-317, 2017.
5. Kaplan RN, Psaila B and Lyden D: Bone marrow cells in the pre-metastatic niche: Within bone and beyond. Cancer Metastasis Rev 25: 521-526, 2006.
6. Roato I: Bone metastases: When and how lung cancer interacts with bone. World J Clin Oncol 5: 149-155, 2014.
7. Bergfeld SA and DeClerck YA: Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 29: 249-261, 2010.
8. Rutkowski MR, Svoronos N, Perales-Puchalt A and Conejo-Garcia JR: The tumor macroenvironment: Cancer-promoting networks beyond tumor beds. Adv Cancer Res 128: 235-262, 2015.
9. Liu Y and Cao X: Characteristics and significance of the pre-metastatic niche. Cancer Cell 30: 668-681, 2016.
10. Liu X and Quan N: Immune cell isolation from mouse femur bone marrow. Bio Protoc 5: e1631, 2015.
11. Sheu CC, Tsai MJ, Chen FW, Chang KF, Chang WA, Chong JW, Kuo PL and Hsu YL: Identification of novel genetic regulations associated with airway epithelial homeostasis using next-generation sequencing data and bioinformatics approaches. Oncotarget 8: 82674-82688, 2017.
12. Chen SC, Chen FW, Hsu YL and Kuo PL: Systematic analysis of transcriptomic profile of renal cell carcinoma under long-term hypoxia using next-generation sequencing and bioinformatics. Int J Mol Sci 18: E2657, 2017.
13. Bolger AM, Lohse M and Usadel B: Trimmomatic: A flexible trimmer for illumina sequence data. Bioinformatics 30: 2114-2120, 2014.
14. Friedlander MR, Mackowiak SD, Li N, Chen W and Rajewsky N: miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res 40: 37-52, 2012.
15. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7: 562-578, 2012.
16. Vejnar CE and Zdobnov EM: MiRmap: Comprehensive prediction of microRNA target repression strength. Nucleic Acids Res 40: 11673-11683, 2012.
17. Brownlie RJ and Zamoyska R: T cell receptor signalling networks: Branched, diversified and bounded. Nat Rev Immunol 13: 257-269, 2013.
18. Huse M: The T-cell-receptor signaling network. J Cell Sci 122: 1269-1273, 2009.
19. Nioungere S, Saltos A and Gray JE: Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. J Thorac Dis 10: S433-S450, 2018.
20. Reungwetwattana T and Dy GK: Targeted therapies in development for non-small cell lung cancer. J Carcinog 12: 22, 2013.
21. Zhu ZJ and He JK: TINCR facilitates non-small cell lung cancer progression through BRAF-activated MAPK pathway. Biochem Biophys Res Commun 497: 971-977, 2018.
22. Burotto M, Chou VL, Lee JM and Kohn EC: The MAPK pathway across different malignancies: A new perspective. Cancer 120: 3446-3456, 2014.
23. Farahani E, Patra HK, Jangamreddy JR, Rashedi I, Kawalec M, Rao Pariti RK, Batakas P and Wiechec E: Cell adhesion molecules and their relation to (cancer) cell stemness. Carcinogenesis 35: 747-759, 2014.
24. Schneider JG, Amend SR and Weilbacher KN: Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions. Bone 48: 54-65, 2011.
25. Schwankhaus N, Gathmann C, Wickleen D, Riecken K, Schumacher U and Valentinier U: Cell adhesion molecules in metastatic neuroblastoma models. Clin Exp Metastasis 31: 483-496, 2014.
26. Ihn HJ, Kim JA, Bae YC, Shin HI, Baek MC and Park EK: Aftatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. BMB Rep 50: 150-155, 2017.
27. Niu G and Chen X: Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets 11: 1000-1017, 2010.
28. Jin GH, Xu W, Shi Y and Wang LB: Celecoxib exhibits an anti-gastric cancer effect by targeting focal adhesion and leukocyte transendothelial migration-associated genes. Oncol Lett 12: 2345-2350, 2016.
29. Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ and Mongan NP: Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 18: 1093-1108, 2009.
30. Cassoni P, Sapino A, Marrocco T, Chini B and Bussolati G: Oxytocin and oxytocin receptors in cancer cells and proliferation. J Neuroendocrinol 16: 362-364, 2004.